


## Thalidomide-NH-amido-PEG3-C2-NH2

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-138856   |
| <b>Molecular Formula:</b> | C <sub>23</sub> H <sub>31</sub> N <sub>5</sub> O <sub>8</sub>                             |
| <b>Molecular Weight:</b>  | 505.52  |
| <b>Target:</b>            | E3 Ligase Ligand-Linker Conjugates  |
| <b>Pathway:</b>           | PROTAC  |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                                     |  |
|-------------------------------------|--|
| <b>Description</b>                  | Thalidomide-NH-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology <sup>[1]</sup> .  |
| <b>IC<sub>50</sub> &amp; Target</b> | Cereblon   |
| <b>In Vitro</b>                     | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### REFERENCES

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. *Front Cell Dev Biol.* 2021;9:629326. Published 2021 Mar 11.

[2]. Nalawansa DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol.* 2020;27(8):998-985.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA